mk 0663 has been researched along with abt 102 in 1 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (abt 102) | Trials (abt 102) | Recent Studies (post-2010) (abt 102) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 23 | 3 | 17 |
| Protein | Taxonomy | mk 0663 (IC50) | abt 102 (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.004 | |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | 0.0031 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Best, AE; Duan, WR; Faltynek, CR; Locke, C; Nothaft, W; Othman, AA; Reeh, P; Schaffler, K | 1 |
1 trial(s) available for mk 0663 and abt 102
| Article | Year |
|---|---|
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Evoked Potentials; Hot Temperature; Humans; Indazoles; Lasers, Gas; Male; Pain; Pain Measurement; Pyridines; Severity of Illness Index; Skin; Sulfones; Tramadol; TRPV Cation Channels; Ultraviolet Rays; Urea | 2013 |